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Epoxyeicosatrienoic acids (EETs) contribute importantly to the regulation of vascular tone and 
blood pressure control. The purpose of this study was to develop stable EET analogs and test 
their in vivo blood pressure lowering effects in hypertensive rats. Using the pharmacophoric 
moiety of EETs, ether EET analogs were designed with improved solubility and resistance 
to auto-oxidation and metabolism by soluble epoxide hydrolase. Ether EET analogs were 
chosen based on their ability to dilate afferent arterioles and subsequently tested for blood 
pressure lowering effects in rodent models of hypertension. Initially, 11,12-ether-EET-8-ZE 
failed to lower blood pressure in angiotensin hypertension or spontaneously hypertensive rats 
(SHR). Esterification of the carboxylic group of 11,12-ether-EET-8-ZE prevented blood pressure 
increase in SHR when injected at 2 mg/day for 12 days (MAP ∆ change at day 8 of injection 
was −0.3 ± 2 for treated and 12 ± 1 mmHg for control SHR). Amidation of the carboxylic group 
with aspartic acid produced another EET analog (NUDSA) with a blood pressure lowering effect 
when injected at 3 mg/day in SHR for 5 days. Amidation of the carboxylic group with lysine 
amino acid produced another analog with minimal blood pressure lowering effect. These data 
suggest that esterification of the carboxylic group of 11,12-ether-EET-8-ZE produced the most 
effective ether-EET analog in lowering blood pressure in SHR and provide the first evidence to 
support the use of EET analogs in treatment of cardiovascular diseases.
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and storage issues with endogenous EETs (Imig et al., 1999; Falck 
et al., 2003a). These EET analogs were designed to resist metabo-
lism and improve solubility and facilitated the identification of 
structure activity relationships for 11,12-EET and 14,15-EET (Falck 
et al., 2003a; Dimitropoulou et al., 2007; Yang et al., 2007; Falck 
et al., 2009). EET analogs vasodilate coronary, cerebral, renal and 
mesenteric arteries, as well as, inhibit vascular smooth muscle cell 
tumor necrosis factor-α-induced vascular cell adhesion molecule-1 
expression (Falck et al., 2003b; Gauthier et al., 2004; Falck et al., 
2009; Sudhahar et al., 2010). Evidence has also supported the use 
of EET analogs in cardiovascular disease. The sulfonimide analog 
of 11,12-EET (11,12-EET-SI) used in vitro improved vascular func-
tion in afferent arterioles taken from hypertensive rats (Imig et al., 
2001). EET analogs also decrease heart damage in animal models of 
cardiac reperfusion injury (Seubert et al., 2007; Gross et al., 2008). 
Recently 11,12-EET analogs based on the 11-nonyloxy-undec-8-
(Z)-enoic acid structure have been generated with better solubility 
and resistance to β-oxidation (Imig and Falck, 2009; Sodhi et al., 
2009). One promising EET analog that has been used successfully 
when administered in vivo is the 11,12-EET analog, NUDSA, that 
is the aspartic amide of 11-nonyloxy-undec-8(Z)-enoic acid (Sodhi 
et al., 2009). The purpose of the current study was to develop EET 
analogs and test their in vivo potential to lower blood pressure in 
rats with hypertension.
IntroductIon
Epoxyeicosatrienoic acids (EETs) are synthesized from arachidonic 
acid by epoxygenase enzymes. These EETs have biological actions 
that suggest that EETs would be beneficial in combating cardio-
vascular diseases (Zeldin, 2001; Spector et al., 2004; Imig, 2005; 
Fleming, 2007). Cardiovascular actions described for EETs include 
identification as endothelium-derived hyperpolarizing factors, inhi-
bition of leukocyte adhesion to the vascular wall, inhibit vascular 
smooth muscle migration, promote endothelial cell proliferation, 
and inhibit platelet aggregation (Campbell et al., 1996; Fisslthaler 
et al., 1999; Node et al., 1999; Sun et al., 2002; Potente et al., 2003; 
Krotz et al., 2004; Hercule et al., 2009). EETs have also been demon-
strated to preserve organ function when added to a transplantation 
preservation solution (Yang et al., 2003). Myocardial infarct size 
following ischemia reperfusion is decreased by the presence of EETs 
in the reperfusion solution (Seubert et al., 2007; Gross et al., 2008). 
However, EET or EET analogs have been used with limited success 
when administered in vivo either acutely or chronically. Given the 
cardiovascular actions attributed to EETs it has been postulated 
that modulation of EETs in cardiovascular diseases has potential 
therapeutic value.
One approach to target EETs for cardiovascular diseases is the 
development of agonistic analogs for the EETs. EET analogs were 
developed for in vitro studies because of the limited solubility 
Frontiers in Physiology | Vascular Physiology  December 2010 | Volume 1 | Article 157 | 2
Imig et al. EET analogs and hypertension
room temperature solution of 11-(nonyloxy)undec-8(Z)-enoic 
acid (170 mg, 0.52 mmol) in anhydrous DMF (5 mL) under 
an argon atmosphere. After stirring 12 h, the reaction mixture 
was diluted with EtOAc (100 mL) and thoroughly washed with 
water (3 × 100 mL), brine (2 × 100 mL), dried over Na
2
SO
4
, and 
evaporated in vacuo. The residue was purified by SiO
2
 column 
chromatography eluting with 50% EtOAc/hexane to afford methyl 
(S)-7-(tert-butoxycarbonylamino)-3-(11-(nonyloxy)undec-8(Z)-
enamido)heptanoate (201 mg, 68% yield) as a colorless oil. 1H 
NMR (CDCl
3
 300 MHz) δ 6.07 (d, J = 6.9 Hz, 1H), 5.44–5.32 
(m, 2H), 4.61–4.54 (m, 2H), 3.72 (s, 3H), 3.41–3.55 (m, 4H), 
3.12–3.04 (m, 2H), 2.30 (q, J = 6.9 Hz, 2H), 2.20 (t, J = 7.8 Hz, 
2H), 2.02–2.00 (m, 2H), 1.64–1.42 (m, 16H), 1.29–1.24 (m, 20H), 
0.85 (t, J = 6.6 Hz, 3H).
To a stirring, 0ºC solution of the above ester (200 mg, 0.35 mm) 
in THF/H
2
O (4:1, 5 mL) was added LiOH (∼2 mL, 1 M aqueous 
solution). After stirring 12 h at room temperature, the  reaction 
MaterIals and Methods
eet analog desIgn and synthesIs
11,12-EET analogs were synthesized for use in experimental pro-
tocols (Figure 1). The synthesis for the following EET analogs have 
been previously described; 11,12-ether-EET-8-ZE (Falck et al., 
2003b), EET-NOX-8-glyceride (Imig and Falck, 2008a), NUSGLY 
(Imig and Falck, 2008a), 14,15-Ether-EEZE (Imig and Falck, 2008a), 
EET-NOX-8-sulfonate (Imig and Falck, 2008b), NUDSA (Sodhi 
et al., 2009), EET-NOX-8-mann (Imig and Falck, 2008b), and EET-
NOX-PEG (Imig and Falck, 2008b).
synthesIs of (s)-7-aMIno-3-[11-(nonyloxy)undec-8(Z)-enaMIdo]
heptanoIc acId hydrochlorIde (nusly)
2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HATU; 224 mg, 0.58 mmol), N
e
-Boc-l-
lysine methyl ester hydrochloride (153 mg, 0.58 mmol), and diiso-
propylethylamine (205 μL) were added sequentially to a stirring, 
Figure 1 | Chemical composition of epoxyeicosatrienoic acid (eeT) analogs.
www.frontiersin.org December 2010 | Volume 1 | Article 157 | 3
Imig et al. EET analogs and hypertension
A baseline arterial pressure was recorded for one week prior to 
the experimental period. Mean arterial pressure was continuously 
recorded throughout the experimental period.
angIotensIn hypertensIon
Telemetry transmitters were implanted into male Sprague-Dawley 
rats (225–275 g) as described. After a week of basal blood pres-
sure recording, osmotic pumps were implanted (s.c.) to deliver 
angiotensin at a dose of 60 ng/min for 3 weeks. In the first series 
of experiments starting on the first day of pump implantation the 
11,12-ether-EET analog was administered (i.p.) once daily for three 
weeks and blood pressure was continuously monitored. The next 
series of experiments were conducted 12 days after pump implanta-
tion. EET analogs were administered (i.p.) as a single dose on day 
12 and blood pressure was monitored for 48 h.
spontaneously hypertensIve rats
Telemetry transmitters were implanted into male spontaneously 
hypertensive rats (SHR) as described. After the surgical recovery 
period, baseline mean arterial pressure was recorded for 1 week. 
In this series of experiments EET analogs were administered 
(i.p.) once daily for various number of days and blood pres-
sure was continuously monitored. Administration of EET ana-
logs was stopped and blood pressure monitored for 4 days after 
treatment withdrawal.
deterMInatIon of nudsa by lIquId chroMatography–
electrospray IonIZatIon–Mass spectroMetry
Samples were analyzed by LC–ESI–MS (Agilent 1100 LC/MSD, 
SL model). Briefly, the samples (5 μl) were separated on a reverse 
phase C
18
 column (Kromasil, 250 × 2 mm) using water/acetonitrile 
containing 0.005% acetic acid as a mobile phase at the flow rate 
of 0.20 mL/min. The mobile phase started at 90% methanol for 
2 min, linearly increased to 100% methanol in 10 min, and held for 
10 min. Drying gas flow was 12 l/min, drying gas temperature was 
350°C, nebulizer pressure was 35 psig, vaporizer temperature was 
325°C, capillary voltage was 3000 V, and fragmentor voltage was 
120 V. The detection was made in the negative mode. For quantita-
tive measurements, the m/z 440 and 311 were used for NUDSA and 
[2H
8
]-AA, respectively. The concentrations of compounds in the 
samples were calculated from the ratios of peak areas to internal 
standard and compared with the standard curves.
statIstIcal analysIs
All data are presented as mean ± SEM. Mean arterial blood pres-
sure and % afferent arteriolar relaxation data were analyzed 
using analysis of variance (ANOVA) for repeated measure-
ments. Differences were considered statistically significant with 
p < 0.05 compared to the control. Analyses were performed using 
GraphPad Prism Version 4.0 software (GraphPad Software Inc, 
La Jolla, CA, USA).
results
eet analogs
Experimental studies of EET analogs in vivo have been hampered 
by difficulties with stability and storage. A series of EET analogs 
was developed and designed to resist esterification, β-oxidation 
mixture was cooled to 0ºC, acidified to pH ∼ 4.5 using oxalic 
acid (∼1 mL, 1 M aqueous solution), and extracted with EtOAc 
(2 × 50 mL). The combined organic extracts were washed with 
water (2 × 100 mL), brine (1 × 100 mL), and dried over Na
2
SO
4
. 
The solvent was removed in vacuo and the residue was subjected to 
Boc-deprotection in THF/H
2
O (1:1, 5 mL) saturated with HCl gas. 
The solvent was evaporated, and dried over high vacuum for 2 h to 
afford the title compound (65 mg, 55% yield). 1H NMR (MeOH-d
4
, 
300 MHz) δ 5.44–5.32 (m, 2H), 4.42–4.34 (m, 1H), 3.41–3.55 (m, 
4H), 2.95–2.82 (m, 4H), 2.29–2.23 (m, 4H), 2.12–1.41 (m, 14H), 
1.37–1.28 (m, 16H), 0.86 (t, J = 4.8 Hz, 3H).
anIMals
Experiments were conducted using male rats and animal proto-
cols were in accordance with National Institutes of Health guide-
lines and approved by the Institutional Animal Care and Use 
Committees. Rats were fed a normal rat chow diet throughout the 
experiment and were housed under conditions of constant tem-
perature and humidity with a 12:12-h light–dark cycle. Rats were 
allowed to adapt to these conditions for several days before starting 
any  experimental procedures.
renal vascular experIMents
We utilized the in vitro juxtamedullary nephron technique to 
evaluate the ability of EET analogs to dilate the afferent arteriole. 
Sprague-Dawley rats were anesthetized with pentobarbital (40 mg/
kg body weight i.p.). The right kidney was isolated and after a mid-
line laparotomy, the right renal artery was cannulated through the 
superior mesenteric artery. The kidney was immediately perfused 
with a Tyrode’s solution containing 6% albumin and a mixture of 
l-amino acids. After the microdissection procedures were com-
pleted, the renal artery perfusion pressure was set to 100 mm Hg. 
The tissue surface was continuously superfused with a Tyrode’s 
solution containing 1% albumin. After a 20-min equilibration 
period, an afferent arteriole was chosen for study, and baseline 
diameter was measured. After the control period, the afferent arte-
riole was constricted with phenylephrine and the increase in diam-
eter was assessed in response to increasing concentrations of EET 
analogs (0.01 nM–1 μm). The afferent arteriole diameter changes 
to EET analogs were monitored for 3 min at each concentration. 
Steady-state diameter to EET analogs was attained by the end of 
the second minute, and the average diameter at the third minute 
was used for statistical analysis.
teleMetry blood pressure MeasureMent
To accurately detect changes in blood pressure and heart rate, 
telemetry transmitters (Data Sciences Inc., St. Paul, MN, USA) 
were implanted in rats 2 weeks prior to the experimental period 
according to manufacturer’s specifications while under sodium 
pentobarbital anesthesia as previously described (Imig et al., 2005). 
In brief, a midline incision was used to expose the abdominal aorta 
that was occluded to allow insertion of the transmitter catheter. The 
catheter was secured in place with tissue glue and the transmitter 
body was sutured to the abdominal wall along the incision line as 
the incision was closed. The skin was closed with staples that were 
removed 7 days later after the incision had healed. Rats were allowed 
to recover from surgery and were returned to individual housing. 
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demonstrates that EET analogs with full vasodilator capacity 
lower blood pressure to a greater extent in SHR. Once daily 
administration for 5 days with EET-NOX-8-glyceride caused a 
minimal decrease in blood pressure whereas NUSLY decreased 
blood pressure by 10 mmHg after 5 days (p < 0.05) and this 
and/or metabolism by sEH. Figure 1 depicts the chemical structures 
of the EET analogs that were synthesized and tested initially for 
vascular activity.
eet analog vascular actIons
We have previously demonstrated that 11,12-ether-EET-8-ZE 
increased mesenteric resistance artery and afferent arteriolar diam-
eter to a similar extent as the endogenous metabolite 11,12-EET 
(Dimitropoulou et al., 2007; Imig et al., 2008). For this study, we 
assessed the afferent arteriolar diameter response to a series of nine 
EET analogs and compared them to 11,12-ether-EET-8-ZE. The 
EET analogs demonstrated a variable ability to dilate afferent arteri-
oles. Afferent arteriolar dilation to the EET analogs became evident 
at concentration of 1 nM and reached a maximum at 10 μM. Four 
of the EET analogs dilated the afferent arteriole to a degree similar 
to 11,12-ether-EET-8-ZE (Figure 2). These four EET analogs with 
activity similar to 11,12-ether-EET-8-ZE as well as an EET analog 
with lesser vasodilatory activity were then assessed for their ability 
to lower blood pressure in hypertension rat models.
EET analogs on blood pressure
We initially assessed the ability of 11,12-ether-EET-8-ZE to lower 
blood pressure in angiotensin and SHR hypertension. Figure 3, 
top panel depicts the effects of 11,12-ether-EET-8-ZE (1 mg/d 
i.p.) administered once daily for three weeks on blood pressure 
angiotensin hypertension. 11,12-ether-EET-8-ZE did not alter 
the progressive increase in blood pressure in response to chronic 
angiotensin infusion. The result of higher 11,12-ether-EET-8-ZE 
doses (10 mg/d or 50 mg/d i.p.) administered to SHR is depicted 
in the bottom panel of Figure 3. As with angiotensin hypertension, 
11,12-ether-EET-8-ZE did not decrease mean arterial blood pres-
sure when administered to SHR.
Next, we compared the ability of a bolus dose of the EET analogs, 
NUDSA (1 mg i.p.) and NUSGLY (1 mg i.p.) with excellent dilator 
activity to an EET analog, EET-NOX-8-glyceride (1 mg i.p.) with 
lesser dilator activity to lower blood pressure in angiotensin hyper-
tension. NUDSA and EET-NOX-8-glyceride both transiently low-
ered blood pressure in rats with angiotensin hypertension. Blood 
pressure in angiotensin hypertensive rats averaged 152 ± 4 mmHg 
and decreased by 52 mmHg within 2 h after administration of 
NUDSA, by 46 mmHg in response to NUSGLY, and by 58 mmHg 
in response to EET-NOX-8-glyceride (Figure 4). The decrease in 
blood pressure to EET-NOX-8-glyceride was very transient and 
blood pressure increased to hypertensive levels by the third hour. 
On the other hand, blood pressure remained lower in NUDSA and 
NUSGLY treated animals throughout the 24-h period and leveled 
of at 135 ± 6 and 143 ± 5 mmHg, respectively, during the last 8 h. 
Heart rate averaged 394 ± 7 bpm and did not change in response 
to NUDSA, NUSGLY, or EET-NOX-8-glyceride administration. 
These results suggested that EET analogs with excellent dilator 
activity could be more effective in lowering blood pressure when 
administered chronically to hypertensive animals.
We then tested five EET analogs for their ability to lower blood 
pressure in SHR. Comparison of an EET analog with full to an 
EET analog with intermediate vasodilator activity is depicted 
in Figure 5. The blood pressure response in SHR treated with 
EET-NOX-8-glyceride (3 mg/d i.p.) or NUSLY (2 mg/d i.p.) 
Figure 2 | eeT analogs can vasodilate afferent arterioles to varying 
degrees. Afferent arteriolar diameter averaged 25.3 ± 0.8 μm (n = 44) at a 
renal perfusion pressure of 100 mmHg and decreased to 14.0 ± 0.6 μm in 
response to 0.5 μM norepinephrine. Top panel depicts the afferent arteriolar 
dilation to ten different EET analogs (10 nM, n = 4–6) and the bottom panel 
depicts the vascular response to a 1 μM dose of the EET analogs. *Dilation is 
significantly less than 11,12-ether-EET-8-ZE (p < 0.05); † alagges dilation is 
significantly less than all other EET analogs (p < 0.05).
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analog dilator activity is just one aspect that can predict in vivo 
blood pressure lowering but other aspects such as bioavailability 
may limit this biological action.
decrease in blood pressure waned in the last 2 days. The results 
of two additional EET analogs with excellent dilator activity 
and an ability to lower blood pressure in the SHR are depicted 
in Figure 6. EET-NOX-8-PEG (2 mg/d i.p.) administered once 
daily for 10 days to SHR decreased blood pressure 10–15 mmHg 
(p < 0.05, top panel). Once daily administration of NUSGLY 
(2 mg/d i.p.) for 8 days lowered blood pressure by 15 mmHg in 
SHR (p < 0.05, bottom panel). In each instance blood pressure 
began to increase in the SHR when the EET analog treatment 
was discontinued. Taken together, these data suggests that EET 
Figure 3 | 11,12-ether-eeT-8-Ze administered chronically does not alter 
blood pressure in two hypertensive animal models. Average 12-h mean 
arterial blood pressures in angiotensin hypertension (top panel) or 
spontaneously hypertensive rats (SHR, bottom panel) administered vehicle or 
11,12-Ether-EET-8-ZE (n = 3–4 per group).
Figure 4 | Blood pressure response to a single bolus injection of eeT 
analogs, NuDSA (top panel), NuSgLY (middle panel), and eeT-NOX-8-
glyceride (bottom panel). NUDSA and NUSGLY decreased blood pressure 
over the entire 24-h period whereas EET-NOX-8-glyceride resulted in a 
transient lowering of blood pressure (n = 1 per group).
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LC/MS method that has a sensitivity to measure 300 pg of NUDSA in 
a plasma sample. NUDSA administered as a bolus injection resulted in 
detectable plasma levels for up to 4 h (Figure 7, bottom panel). There 
was also very little evidence for rapid metabolism of NUDSA. These 
data demonstrate that NUDSA is bioavailable and plasma levels can 
reach a level that correlates with the anti-hypertensive actions.
dIscussIon
Epoxyeicosatrienoic acids have cardiovascular actions that impli-
cate them as important contributors to vascular function and blood 
pressure control (Zeldin, 2001; Spector et al., 2004; Imig, 2005; 
nudsa on blood pressure and plasMa levels
Next we tested the effect of NUDSA that had excellent vasodilator 
activity and has previously been demonstrated to lower blood pres-
sure in a mouse model of metabolic syndrome (Sodhi et al., 2009). 
Administration of NUDSA (3 mg/d i.p.) for 5 days lowered blood 
pressure by 10 mmHg in SHR (p < 0.05, Figure 7, top panel). We 
then developed an analytical method to measure plasma levels of 
our lead EET analog, NUDSA that demonstrated in vivo blood pres-
sure lowering in angiotensin hypertension and SHR. A quantitative 
Figure 6 | Two eeT analogs administered chronically decrease blood 
pressure in spontaneously hypertensive rats (SHr). Average 12-h mean 
arterial blood pressures in SHR administered EET-NOX-8-PEG for ten days (top 
panel) or NUSGLY for 8 days (bottom panel) compared to vehicle (n = 3–4 per 
group). *Blood pressure is significantly less than vehicle treated SHR 
(p < 0.05).
Figure 5 | Comparison of an eeT analog with intermediate vasodilator 
activity, eeT-NOX-8-glyceride, to on with full vasodilator activity, NuSLY 
on blood pressure in spontaneously hypertensive rats (SHr). Average 
12-h mean arterial blood pressures in SHR administered EET-NOX-8-glyceride 
for 5 days (top panel) or NUSLY for one week (bottom panel) compared to 
vehicle (n = 3–4 per group). *Blood pressure is significantly less than vehicle 
treated SHR (p < 0.05).
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Figure 7 | NuDSA decreases blood pressure in blood pressure in 
spontaneously hypertensive rats (SHr). Average 12-h mean arterial blood 
pressures in SHR administered NUDSA for 5 days (top panel). Time course for 
NUDSA plasma concentration after i.p. administration to rats. Graph depicts 
increase in plasma NUDSA over a 1-day period (bottom panel). LC–MS was 
able to detect NUDSA (inset). Inset: (A) Top depicts NUDSA standard, middle 
depicts [2H8]-arachidonic acid standard and bottom depicts combined. Inset: 
(B) Same as panel A from a plasma sample. *Blood pressure is significantly 
less than vehicle treated SHR (p < 0.05).
Fleming, 2007). An avenue being explored for potential therapeu-
tic application is the development of EET analogs. EET analogs 
have the potential to have greater beneficial effects in hypertension 
since EETs have anti-inflammatory and anti-platelet aggregatory 
properties (Falck et al., 2003b; Krotz et al., 2004; Imig et al., 2005). 
We generated a series of 11,12-EET analogs and determined their 
vascular actions in vitro and subsequently tested a subset of this 
series for their ability to lower blood pressure in hypertension when 
administered chronically. We found that esterification of the car-
boxylic group of 11,12-ether-EET-8-ZE with aspartic acid produced 
the most effective anti-hypertensive EET analog in the series.
Epoxyeicosatrienoic acids analogs of 11,12-EET and 14,15-EET 
and EET antagonists have been used for many years to examine 
the cardiovascular actions attributed to EETs (Gauthier et al., 
2004; Sudhahar et al., 2010). In particular, analogs of 11,12-EET 
and 14,15-EET have been used to identify structure activity rela-
tionships and cell signaling mechanisms that are responsible for 
vasodilation (Falck et al., 2003a; Dimitropoulou et al., 2007; Imig 
et al., 2008). These studies have determined that an acidic carboxyl 
group in carbon 1, an ∆8 double bond, 20-carbon chain length, 
and a cis epoxide are required for full vasodilator activity (Falck 
et al., 2003a; Dimitropoulou et al., 2007; Imig et al., 2008). We 
have previously determined that 11,12-ether-EET-8-ZE dilated 
renal and mesenteric arteries to an extent similar to endogenous 
11,12-EET (Dimitropoulou et al., 2007; Imig et al., 2008). A series 
of analogs were then synthesized and tested for afferent arteriolar 
dilator activity. Modifications were made to the carboxylic group 
of 11,12-ether-EET-8-ZE to confer resistance to β-oxidation. 
11,12-EET analogs containing an ∆8 double bond and an ether 
at the 11,12 position dilated afferent arterioles. Three of these 
EET analogs were similar to 11,12-ether-EET-8-ZE in respect to 
vasodilatory capacity. Other modifications to the carboxylic group 
resulted in EET analogs with an intermediate ability to dilate affer-
ent arterioles. As would be expected, 14,15-ether-EEZE that lacks 
an ∆8 double bond failed to dilate the afferent arteriole. These 
findings determined that modifications to the carboxylic group 
of 11,12-ether-EET-8-ZE result in EET analogs that have similar 
or slightly diminished vasodilatory activity.
Even though EET analogs have been used in cell culture and 
in vitro systems for many years, there has been limited success 
with in vivo administration in either the acute or chronic setting. 
11,12-Ether-EET-8-ZE did not alter blood pressure in angiotensin 
hypertension or SHR when administered chronically for a period of 
days and weeks. Since 11,12-ether-EET-8-ZE contains a carboxylic 
group that is susceptible to esterification and β-oxidation, we devel-
oped another series of EET analogs. In this study we determined 
that modification of the carboxylic group to resist β-oxidation 
resulted in EET analogs that decreased blood pressure in hyper-
tension. Interestingly, EET-NOX-8-glyceride that had intermedi-
ate vasodilatory activity transiently decreased blood pressure in 
angiotensin hypertension and did not significantly lower blood 
pressure in the SHR when administered over a 5-day period. On the 
other hand, NUDSA that vasodilated the afferent arteriole similar 
to 11,12-ether-EET-8-ZE decreased blood pressure in angiotensin 
hypertension over a 24-h period and decreased blood pressure over 
a 5-day period in SHR. These decreases in blood pressure were not 
accompanied by a change in heart rate. A recent study determined 
the ability of NUDSA to ameliorate the metabolic syndrome phe-
notype in heme-oxygenase 2 null mice (Sodhi et al., 2009). NUDSA 
decreased blood pressure and prevented obesity-associated vascu-
lar and kidney damage in metabolic syndrome mice (Sodhi et al., 
2009). This study and the results of the current study demonstrate 
a first step toward the therapeutic application of EET analogs for 
cardiovascular diseases.
One aspect that was not determined in the experimental study 
where mice were chronically administered NUDSA was bioavail-
ability. We developed an LC–MS method to determine NUDSA 
levels in rat plasma. An injection of NUDSA was given and plasma 
levels determined at different time points. Plasma levels of NUDSA 
peaked 2 h after administration and were significantly lower at 8 h. 
We did not determine clearance, metabolism, or tissue NUDSA 
 levels in the current study. A more thorough pharmacokinetic 
analysis would be necessary if this or another EET analog was 
developed for preclinical trials.
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In conclusion, we developed a series of EET analogs and 
evaluated their ability to dilate afferent arterioles and lower 
blood pressure in angiotensin hypertension and SHR. Amidation 
of the 11,12-ether-EET-8-ZE carboxylic group with aspartic acid 
resulted in a promising EET analog that possessed vasodila-
tory activity and lowered blood pressure in hypertension. 
These experimental findings provide evidence for the possible 
future use of EET analogs for the treatment of cardiovascular 
diseases.
